14 results about "Chlorin" patented technology

The invention belongs to the technical fields of medical chemistry, new materials and nanotechnology, and relates to a novel diagnosis and treatment agent in the field of interdisciplinary, in particular to a preparation method of a reduction response activation < 19 > F magnetic resonance signal amplification self-degradation nanometer diagnosis and treatment micelle. Poly (benzyl carbamate) is obtained through condensation polymerization as a basic structure, then chemical modification is performed to obtain a self-degradable fluorine-containing amphiphilic block polymer, hydrophobic drug chlorin (Ce6) is loaded through self-assembly, the self-degradable fluorine-containing amphiphilic block polymer has the characteristic of responding to degradation of glutathione (GSH) at a tumor site, and on the basis of maintaining self-degradation of a hydrophobic chain segment of the nano-micelle, the self-degradable fluorine-containing amphiphilic block polymer can be used for preparing the self-degradable fluorine-containing amphiphilic block polymer. The nano-micelle loaded with Ce6 has the advantages that the nano-micelle loaded with Ce6 is used as a carrier, the characteristic of efficient 19F MR imaging is additionally endowed, under laser irradiation, the nano-micelle loaded with Ce6 can enhance a new scheme of breast cancer photodynamic therapy, the effects of responding to tumor microenvironment self-degradation drug release and 19F MRI signal amplification are achieved, and therefore diagnosis and treatment integration of breast cancer is achieved.

The application provides a method for monitoring lipid oxidation tendency, and belongs to the technical field of fluorescent probe detection. The method utilizes the fluorescence characteristics of a BODIPY molecular probe, and through selecting a molecular probe with a specific structure, directional reaction occurs between the BODIPY molecular probe and oxygen free radicals generated by lipid oxidation at a specific pH value. The conjugated system of the BODIPY molecular probe is destroyed, the half-chlorin structure is broken, and the fluorescence color changes from red to blue-green. According to the change of the fluorescence color before and after the reaction, the visualization monitoring of the lipid oxidation tendency and spatial distribution is realized through fluorescence imaging.

This invention discloses a method and apparatus for preparing dihydroporphyrin supramolecular assemblies, belonging to the field of functional nanomaterials technology. By designing a Y+S composite microfluidic chip, this invention utilizes Dean's vortex induced by an S-shaped flow channel to precisely control the nucleation and growth kinetics of Ce6 molecules, achieving the directional preparation of nanospherical Ce6 supramolecular assemblies. Simultaneously, it ensures that the assemblies have a narrow particle size distribution (PDI < 0.1), completely solving the problems of large morphological heterogeneity and poor controllability in traditional methods, and providing technical support for the standardized preparation of Ce6-based nanodelivery systems.

Methods for increasing the density and diameter of human hair comprised of the step of applying to any skin area of the body and / or the scalp covered with hair, a topical hair volumizing composition comprised of a chelated copper chlorin compound, wherein the chelated copper chlorin compound is comprised of at least 75% of a chlorin species selected from the group consisting of trisodium copper (II) chlorin e6 and disodium copper (II) isochlorin e4, and the chelated copper chlorin compound is present at a concentration of from 0.02 to 0.1% by weight of the composition.

The invention discloses a dihydroporphin photosensitizer, pharmaceutically acceptable salts thereof, a preparation method and application, and belongs to the technical field of medicines. The structure of the photosensitizer is shown as a formula I, and the photosensitizer is prepared from chlorin E6 through esterification, selective hydrolysis and decarboxylation reaction and has the advantages of being single in chemical component, high in stability and high in photodynamic anti-tumor activity. In-vitro and in-vivo experiments show that the compound has a remarkable killing effect on various tumor cells, IC50 is lower than 10 mu g / mL, the tumor inhibition rate is up to 100%, and the compound is suitable for preparing anti-tumor drugs, has no obvious toxic or side effect and has clinical application potential. # imgabs0 #

Biologically active compounds that can be used as photosensitizers for diagnostic and therapeutic applications, particularly for PDT of cancer, infections and other hyperproliferative diseases, fluorescence diagnosis and PDT treatment of a non-tumorous indication such as arthritis, inflammatory diseases, viral or bacterial infections, dermatological, opthamological or urological disorders are provided as well as providing methods to obtain them in pharmaceutical quality. One embodiment consists of a method to synthesize a porphyrin with a defined arrangement of meso-substituents and then converting this porphyrin system to a chlorin system by dihydroxylation or reduction, and if more than one isomer is formed separate them by chromatography either on normal or reversed phase silica. In another embodiment the substituents on the porphyrin are selected to direct the reduction or dihydroxylation to the chlorin so that a certain isomer is selectively formed. Another embodiment is to provide amphiphilic compounds with a higher membrane affinity and increased PDT-efficacy. In other embodiments the nucleophilic substitution on pentafluorophenyl-substituted tetrapyrroles is used to obtain compounds with a high PDT-efficacy. In another embodiment substituents are identified that via their steric and / or electronic influence direct the dihydroxylation or reduction with diimine so that one isomer is favored. Another embodiment consists of formulating the desired tetrapyrrole photosensitizer into a pharmaceutical formulation to be injected into the body avoiding undesirable effects like solubility problems or delayed pharmacokinetics of the tetrapyrrole systems.

The present invention describes a method for obtaining a functionalized polymer surface (MPn-PSm) from a polymer or copolymer of an appropriate functionalization (X); the polymer or copolymer can be a halogen or leaving group, such as polyvinyl chloride (MP1) and (chloromethyl) polystyrene-Merrifield (MP2), as well as a curcumin photosensitizer (PS1), meso-tetra(aryl)porphyrin, a chlorin or bacterial chlorin (PS2) halogenated and functionalized by a nucleophilic group, particularly including P2 of the meso-imidazolyl-porphyrin, chlorin or bacterial chlorin (PS3) type. The structures of all photosensitizers in this application contain functional groups (Y) hydroxyl (OH), sulfhydryl (SH) or NH2 nucleophiles. The application also describes a process in which photosensitizer PS1-PS3 is covalently bonded to a functional polymer material MP1-MP2 by a nucleophilic substitution reaction to prepare an MPn-PSm product. The product formed prevents the proliferation of microorganisms, thereby preventing serious infections - one of the main causes of death in patients using these devices.

The present invention relates to small cationic ortho-5,15-di-heteroaryl porphyrin derivatives, in particular porphyrins, chlorins or bacteriochlorin of formula (I) or pharmaceutically acceptable salts thereof.This invention also relates to the use of the above-mentioned cationic ortho-5,10-di-heteroaryl porphyrin derivatives of Formula (I) or a pharmaceutically acceptable salts thereof, in photodynamic inactivation of microorganisms, where the referred derivatives are able to treat the same in the presence of an adequate light.The present invention also describes pharmaceutical compositions comprising one or more of the cationic ortho-5,10-di-heteroaryl porphyrin derivatives, in particular prophyrins, chlorins or bacteriochlorins of Formula (I), or pharmaceutically acceptable salts thereof, for the treatment of bacterial and / or fungi and / or yeasts and / or viral infections, in humans or animals.

The invention discloses a colloid self-assembly crystal monolayer film with photodynamic and immunoregulation functions, a preparation method and application, the colloid self-assembly crystal monolayer film (BCCe6) is composed of SiO2-MnO2 particles and PSC-Ce6 particles, and a photosensitizer is chlorin e6. The diameter of the SiO2 particles is 4 to 6 m, and the diameter of the PSC particles is 300 to 500 nm; the density of the SiO2-MnO2 particles is 2.19 to 2.65 g / cm < 3 >, and the density of the carboxylated polystyrene particles modified by the photosensitizer is 0.96 to 1.05 g / cm < 3 >; the surface structure of the colloid self-assembly crystal monolayer film is a regular hexagonal close-packed structure, and the depth of a groove is 300-900 nm. The colloidal self-assembly crystal single-layer film can slowly release Mn < 2 + > ions and release ROS under the stimulation of near-infrared light, and efficient sterilization and macrophage phenotype rapid conversion are achieved through the cooperation of a surface physical structure and a chemical effect. The colloidal self-assembled crystal monolayer film is placed on a bacterial infected wound, and is removed after being irradiated by infrared light for 5-10 minutes, so that the healing of the wound can be accelerated.

The present invention generally relates to the formation, chemistry and application of biologically active compositions. More particularly, the present invention relates to certain dyes, specifically porphyrin and chlorin derivatives, in combination with inventive polymers, i.e. light-cleavable polymers, that can be used as photosensitizer compositions for a wide range of light irradiation treatments such as photodynamic therapy of cancer, infections and other diseases. The dye derivatives may either be adsorbed on, or incorporated in, or attached to specific polymers, which as well form part of the invention.

The present invention describes methods for obtaining functionalized polymeric surfaces (MPn-PSm) from polymers or copolymers with appropriate functionalizations (X), which can be a halogen of a leaving group, such as polyvinyl chloride (MP1) and (chloromethyl) polystyrene-Merrifield (MP2), and curcumin photosensitizers (PS1), meso-tetra(aryl) porphyrins, chlorins or bacteriochlorins halogenated and functionalized with nucleophilic groups (PS2), in particular including P2 of the type meso-imidazoyl-porphyrins, chlorins or bacteriochlorins (PS3). The structures of all the photosensitizers in the present application incorporate a functional group (Y), which is a OH, SH or NH 2 nucleophile. The application also describes the covalent bonding process of the photosensitizers PS1-PS3 to the functional polymeric materials MP1-MP2 by means of a nucleophilic substitution reaction to prepare the MPn-Psm products. The formed products prevent microbial proliferation, which can cause the serious infections that are one of the main causes of death in patients using these devices.

The present invention relates to chlorin e6 analogs and pharmaceutically acceptable salts thereof, and compositions comprising chlorin w6 analogs and pharmaceutically acceptable salts thereof. The chlorin e6 analogs and pharmaceutically acceptable salts thereof are suitable for use in photodynamic therapy, cytoluminescence therapy, and photodynamic diagnosis, for example, for the treatment or detection of tumors or antiviral treatment. The present invention also relates to the use of chlorin e6 analogs and pharmaceutically acceptable salts thereof in the manufacture of phototherapeutic or photodiagnostic agents, and to methods of photodynamic therapy, cytoluminescence therapy, or photodynamic diagnosis, for example, for the treatment or detection of tumors or antiviral treatment. [Formula 1] TIFF2025539865000117.tif70159

The application discloses a reversible coordination type rare earth nanocrystal-organic dye, which comprises a rare earth nanocrystal and a chlorin dye, and the chlorin dye forms reversible coordination with the rare earth nanocrystal on the surface of the rare earth nanocrystal, wherein the chlorin dye has the structure shown in formula I: wherein R is halogen or a group * indicates a bonding position. The reversible coordination type rare earth nanocrystal-organic dye can form reversible coordination, the structure of the organic dye is not damaged, continuous detection can be carried out, the sensitivity of detection is high, and the anti-interference capability is strong. The application further discloses a preparation method of the reversible coordination type rare earth nanocrystal-organic dye, a luminescent probe, application of the luminescent probe in biological detection, and a method for detecting gastric juice pH by using the luminescent probe.

The application discloses a kind of no excitation small molecule photosensitizer drug and preparation method and application, belong to clinical metastatic cancer treatment drug technical field, solve the defects of PDT itself in prior art, it has the technical problems such as low efficiency, weak targeting, large side effect in deep tissue metastatic tumor treatment.The no excitation small molecule photosensitizer drug provided by the application is that photosensitizer molecules are connected in single molecule by covalent coupling method with energy donor and acceptor, synthesizes intramolecular CRET chemiluminescence imaging treatment probe, energy acceptor is photosensitizer, energy donor is peroxysuccinate compound or its derivative;Energy acceptor photosensitizer is chlorin photosensitizer, photosensitizer P is near-infrared photosensitizer chlorin Cy7, peroxysuccinate group C is oxalyl chloride ethyl ester, and the specific reaction is that Cy7 and oxalyl chloride ethyl ester are connected by esterification covalent reaction, to prepare photosensitizer molecular drug Cy7-EOM based on intramolecular CRET, realize effective photodynamic therapy to deep tissue metastatic tumor.